| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.005 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.005 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.005 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.16 | 0.006 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.006 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.006 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.007 |